Apomorphine – Treatment Guidelines for Initiation ...
Canberra Hospital and Health ServicesClinical Procedure Apomorphine – Treatment Guidelines for Initiation, Administration and Monitoring of Adults with Parkinson’s DiseaseContents TOC \o "3-3" \h \z \t "Heading 1,1,Heading 2,2" Contents PAGEREF _Toc507921352 \h 1Purpose PAGEREF _Toc507921353 \h 3Alerts PAGEREF _Toc507921354 \h 3Scope PAGEREF _Toc507921355 \h 3Section 1 – Background PAGEREF _Toc507921356 \h 3Section 2 – Administration options PAGEREF _Toc507921357 \h 42.1 Intermittent Subcutaneous Injections PAGEREF _Toc507921358 \h 42.2 Continuous Subcutaneous Infusion PAGEREF _Toc507921359 \h 4Section 3 – Referral Process PAGEREF _Toc507921360 \h 43.1 Internal Referral Process PAGEREF _Toc507921361 \h 43.2 External Referral Process PAGEREF _Toc507921362 \h 5Section 4 – Pre-Admission PAGEREF _Toc507921363 \h 7Section 5 – Apomorphine Challenge PAGEREF _Toc507921364 \h 7Section 6 – Titration post Apomorphine Challenge PAGEREF _Toc507921365 \h 96.1 Continuous Subcutaneous Infusion PAGEREF _Toc507921366 \h 96.1.1 Pump Flow Rate PAGEREF _Toc507921367 \h 96.1.2 Bolus Dose PAGEREF _Toc507921368 \h 9Section 7 – Post discharge PAGEREF _Toc507921369 \h 10Implementation PAGEREF _Toc507921370 \h 11Related Policies, Procedures, Guidelines and Legislation PAGEREF _Toc507921371 \h 11References PAGEREF _Toc507921372 \h 12Definition of Terms PAGEREF _Toc507921373 \h 12Search Terms PAGEREF _Toc507921374 \h 12Attachments PAGEREF _Toc507921375 \h 12Attachment 1 – Tomlinson Levodopa Conversion Table PAGEREF _Toc507921376 \h 14Attachment 2 – Patient Selection Guidelines for Commencement of Apomorphine Therapy PAGEREF _Toc507921377 \h 15Attachment 3 – Joint Position Statement on Apomorphine Hydrochloride PAGEREF _Toc507921378 \h 16PurposeThe purpose of this procedure is to provide a pathway for the commencement of Apomorphine therapy for patients with Parkinson’s disease at the Canberra Hospital and Health Services (CHHS). Back to Table of ContentsAlertsApomorphine may induce nausea and vomiting and it is recommended to commence 10mg Domperidone three times daily (TDS) at 48-72 hours prior to an Apomorphine Challenge (section 5), then continue for 3-7 days in total, or as required.Apomorphine may cause hallucinations and impulse control disorder and close monitoring is essential during the initiation phase. Apomorphine is NOT morphine, nor does it have any analgesic or addictive properties.Back to Table of ContentsScopeThis document applies to adults with a diagnosis of Parkinson’s disease and who have been identified as potentially eligible to commence Apomorphine therapy.This document applies to the following staff working within their scope of practice:Medical OfficersNurses and Midwives PharmacistsStudents under direct supervision.Back to Table of ContentsSection 1 – BackgroundApomorphine is a potent dopamine agonist considered an effective therapy for Parkinson’s disease. It is a Schedule 100 medication and cannot currently be prescribed by General Practitioners in the ACT. Apomorphine mimics the role of dopamine, ultimately assisting to control body movement. Apomorphine will not work for every person with Parkinson’s and patients must meet certain criteria, see Attachment 2, to start Apomorphine treatment. Apomorphine is a viable option for patients who no longer gain adequate control of their symptoms through oral dopaminergic treatment.Apomorphine’s effectiveness is measured through a series of assessments pre and post administration of the medication. These assessments must be completed within specific time frames and by individuals qualified to do so. Back to Table of Contents Section 2 – Administration optionsApomorphine can be administered using two different options based on the symptoms present in the patient being trialled. The referring Medical Officer should indicate which administration option they are aiming to achieve.2.1 Intermittent Subcutaneous InjectionsPatients who experience unpredictable or predictable ‘OFF’ periods are suited for intermittent subcutaneous injections of Apomorphine as an ‘on-demand’ therapy. 2.2 Continuous Subcutaneous InfusionSuitable for patients who are unable to achieve adequate ‘ON’ periods on oral dopaminergic therapy alone or who experience significant Levodopa Induced Dyskinesia (LID). Back to Table of Contents Section 3 – Referral ProcessApomorphine Challenge, see Section 5, and initiation will be done under supervision and guidance from a Neurologist with the support from the Parkinson’s Advanced Practice Nurse (APN). 3.1 Internal Referral ProcessProcedure Once a patient is identified as suitable for initiation of Apomorphine the Neurologist or Geriatrician must:Confirm diagnosis and ensure the patient meets Pharmacy Benefits Scheme (PBS) criteria under Section 100.Obtain informed written consent.Request baseline tests:Electrocardiogram (ECG)Full blood count (FBC)Liver function test (LFT)Urea, electrolytes and creatinine (UEC)Erythrocyte sedimentation rate (ESR)Coombs test (for haemolytic anaemia).Once a patient is identified as suitable by their CHHS Neurologist or Geriatrician for initiation of Apomorphine, a referral is made to the Parkinson’s APN via email for education and pre-admission information. The Parkinson’s APN will allocate a 120 minute appointment to provide education and pre-admission information. During this appointment, the Parkinson’s APN will conduct the following assessments:United Parkinson’s Disease Rating Scale (UPDRS)Montreal Cognitive Assessment (MoCA)Questionnaire for Impulse Control Disorders (QUIP) Electrocardiogram (ECG)Blood Pressure – standing/sitting (BP)The following documents are sent to the patient prior to the appointment for completion:Parkinson’s Disease Questionnaire - (PDQ-39)Freezing of Gait Questionnaire - (FOG-Q)Parkinson’s Diary The Parkinson’s APN will report back to the referring Neurologist or Geriatrician and the decision on whether to proceed to Apomorphine Challenge will be made.The Parkinson’s APN will use the Apomorphine Challenge Education Checklist, which can be found on the Clinical Forms Register, to document that all education requirements have been met, including how to access ongoing consumables.Once approved for a trial of Apomorphine a ‘Planned Hospital Admission Booklet’ must be completed by the accepting/treating Neurologist or Geriatrician for admission to conduct an Apomorphine Challenge. The Neurologist or Geriatrician also needs to provide the patient with a script. The Neurologist or Geriatrician must indicate whether the patient is to continue on intermittent subcutaneous injection or continuous subcutaneous infusion post the Apomorphine Challenge. Note: In line with best practice principles trialling of Apomorphine will be done in an inpatient environment as patients are required to withhold oral dopaminergic agents prior to trial commencement; this can cause significant bradykinesia and rigidity which would make traveling a considerable inconvenience. 3.2 External Referral ProcessProcedurePatients identified as potentially suitable to commence Apomorphine therapy will require a referral to be addressed to a Neurologist at the Canberra Hospital and Health Services.The referring Medical Officer should provide the patient with a blood request form including the following tests:FBCLFTUECESRCoombs test (for haemolytic anaemia)The referral is triaged as a Category 2 and the patient is allocated an appointment time with a Neurologist to be assessed for eligibility. If assessed as eligible by the Neurologist, the Parkinson’s Advanced Practice Nurse (APN) will allocate a 120 minute appointment to provide education and pre-admission information. During this appointment the Parkinson’s APN will conduct the following assessments:UPDRSMoCAQUIPECGBP – standing/sitting The following documents are sent to the patient prior to appointment for completion:PDQ-39FOG-QParkinson’s Diary The Parkinson’s APN will use the Apomorphine Challenge Education Checklist, which can be found on the Clinical Forms Register, to document that all education requirements have been met, including how to access ongoing consumables. The Parkinson’s APN will initiate completing the Parkinson’s Apomorphine Challenge Guideline, which can be found on the Clinical Forms Register.Once approved for a trial of Apomorphine a Planned Hospital Admission Booklet (as found on the clinical forms register) must be completed by the accepting/treating Neurologist for admission to conduct an Apomorphine Assessment. Note: In line with best practice principles trialling of Apomorphine will be done in an inpatient environment as patients are required to withhold oral dopaminergic agents prior to trial commencement; this can cause significant bradykinesia and rigidity which would make traveling to the hospital a safety risk for the patient. Back to Table of Contents Section 4 – Pre-Admission The Neurologist or Geriatrician will:Complete plete Planned Hospital Admission Booklet, found on the clinical forms rm on-call Neurologist of Apomorphine initiation (for additional medical support during admission).Ensure a medication order is completed.The Parkinson’s APN will:Organise a planned admission, as per CHHS Admission to Discharge procedure, to 7A and notify Hospital in the Home (HITH) to ensure they have capacity to admit the patient post Apomorphine Challenge.Contact the patient and provide admission instructions.Remind the patient that their medication will be withheld on admission.Arrange with pharmacy to have the Apomorphine available and delivered to the ward on day of admission.Educate and support ward staff about the procedure prior to admission.Schedule Apomorphine Challenge on any week day.Back to Table of Contents Section 5 – Apomorphine ChallengeThe patient will be assessed using three separate challenge doses of Apomorphine: 2mg, 3mg, and 5mg. The aim is to achieve an ‘ON’ period within 7-10 minutes and duration effect of roughly 45-60 minutes. There will be a minimum of 45 minutes between each dose to allow for the drug to ‘wear-off’ prior to dosage increment. The entire Apomorphine Challenge is expected to take 4-5 hours to complete (however this may vary based on individual response). Equipment Apomorphine (Movapo?) solution for injection ampoule 20mg/2mL3 x 1mL syringes3 x Chlorhexidine SwabsKidney dishParkinson’s - Apomorphine Challenge template, as found on the clinical forms register.ProcedureOn admission:The Parkinson’s APN will use the Parkinson’s - Apomorphine Challenge template to document the following information after confirming with the patient:Their name, Date of Birth and Unique Record Number (on the patient record)If they have any allergiesThey consent to the procedureThey understand the procedureThe reason for conducting the Apomorphine ChallengeCurrent Parkinson’s medicationsOther medications for Parkinson’s that they have trialledThat they have been assessed and deemed as having stable cardiac, renal, respiratory and psychiatric functionAll Parkinson’s medication have been withheld for a minimum of six hours prior to challenge – this ensures an ‘OFF’ stateAny dopamine agonist medications have been withheld for at least twelve hoursNote: The patient is NOT required to be nil by mouth – only withhold Parkinson’s medications. Medication is to be administered as per the Medication Handling Policy located on the policy register.The Parkinson’s APN will:record a set of baseline vital signsconduct a UPDRS assessment to establish ‘OFF’ baseline – use the Parkinson’s - Apomorphine Challenge template, which can be found on the Clinical Forms Registeradminister the first dose (2mg) of Apomorphine into the selected site (abdomen/thigh) conduct another UPDRS assessment 10 minutes after administration of first doseadministered the second dose (3 mg) of Apomorphine into the selected site (abdomen/thigh) conduct another UPDRS assessment 10 minutes after administration of second doseadministered the third dose (5mg) of Apomorphine into the selected site (abdomen/thigh) conduct another UPDRS assessment 10 minutes after administration of third doseThe Apomorphine percentage response will be calculated, as per template instructions, and reported back to the treating Neurologist or GeriatricianThe treating Neurologist or Geriatrician will decide the discharge/transfer of the patient accordingly:Intermittent subcutaneous injections: to home (as long as the patient is stable) Continuous subcutaneous infusion: to HITH (as long as the patient is stable) with the following documentation to be completed by HITH staff prior to transfer:Referral and Consent for Treatment Hospital in the Home (as found on the clinical records forms register)Titration plan as prescribed by Neurologist or Geriatrician.Note: If the patient achieves adequate ‘ON’ after the second dose, the third dose of Apomorphine can be withheld.Back to Table of Contents Section 6 – Titration post Apomorphine ChallengeIt is expected that the patient achieves a percentage response of at least 30% in order to continue on Apomorphine therapy, any response below 30% is considered a failed challenge. If the patient fails the challenge they are considered unresponsive and are deemed not suitable for ongoing Apomorphine. 6.1 Continuous Subcutaneous InfusionOnce the Apomorphine Challenge has been completed on the ward the patient will be transferred to HITH for ongoing monitoring and dose titration. HITH staff will be supported by the Parkinson’s APN under direction from the treating/accepting Neurologist or Geriatrician to ensure titration is done correctly. Additionally, as and when necessary, the APN/HITH nurses can take help from the nurses of the product manufacturer.Once the successful challenge dose is determined, the starting rate of the Apomorphine infusion will be set at half this dose; i.e. if the challenge dose was determined to be 5mg, the starting continuous infusion rate will be 2.5mg/hr. The recommended titration rate is 0.5mg/hr weekly with simultaneous reduction of oral medications calculated to the approximate Levodopa Equivalent Dosage (LED) using the Tomlinson table in Attachment 1.6.1.1 Pump Flow RateStarting Rate: _____________mg/hr = (_____mL/hr)Range: ________mg/hr to ______mg/hr (_______mL/hr to ______mL/hr)6.1.2 Bolus Dose Bolus dose: _____________mg = (_____mL)Lockout time: ________Range: ________mg to ______mL (_______mg to ______mL)The patient will be reviewed on a regular basis, determined by the individual Specialist and as required in their clinic. The patient will be provided with the Parkinson’s APN contact phone number for ongoing support of their Apomorphine Therapy. Patients will also be provided with the Nurse Advisor contact details from the product manufacturer for additional support.The patient will be provided with login instructions to enable them to order consumables using the mobile application: myINTERACT? and given supporting documentation on how to troubleshoot pump errors.If at any stage the patient, or their carer, is no longer able to self-manage the pump due to a short-term illness or injury a referral should be made to the Community Care Program for support during this time. Community Care Program nursing staff will be educated and supported by the Parkinson’s APN. Note: In the event of after-hours presentation to hospital an ‘Apomorphine Kit’ will be accessible to the after-hours hospital manager to assist with trouble shooting the device.Back to Table of Contents Section 7 – Post dischargeA copy of the Parkinson’s - Apomorphine Challenge form will be sent to the General Practitioner along with a report outlining the following:Patient response including calculated UPDRS percentage improvement (use Apomorphine percentage response calculation, as per template instructions)Instructions for ongoing treatment – intermittent or continuous infusionIntermittent: dosage and frequencyContinuous: Pump flow rateBolus doseLock out timeOngoing monitoring requirements – to be done every 6-12monthsFull Blood Count (FBC) – check for:White Cell Count (WCC) < 4 x 10?/LNeutrophils < 1.8 x 10?/LPlatelets < 150 x 10?/LLiver Function Test (LFT) – check for:ALT > 55u/LUrea Creatinine Electrolytes (UEC) – check for:Creatinine > 90mmol/LPotassium > 5mmol/LCoombs Test – check for:Positive (for haemolytic anaemia)Instructions advising what to do in the event of pump failure:Contact Specialist and ensure oral Parkinson’s medications are continued.Note: If the patient presents with blood results outside of the above mentioned ranges please cease treatment and contact the treating Neurologist or Geriatrician as a matter of urgency.Other adverse events:HallucinationsImpulse Control DisorderSevere orthostatic hypotensionSevere nausea/vomitingIf these adverse events occur please contact the treating Neurologist or Geriatrician and consider cessation of treatment under guidance from a Neurologist or Geriatrician. Back to Table of Contents Implementation This procedure will be presented to staff during educational in-services and an eLearning package exists on Capabiliti for staff to complete.Any staff required to make changes to the Crono Apo-Go 111 pump must be credentialed by the Parkinson’s APN after completing the eLearning package.The procedure will be available to all staff on the policy register.Back to Table of ContentsRelated Policies, Procedures, Guidelines and LegislationPoliciesHealth Directorate Nursing and Midwifery Continuing Competence PolicyConsent and Treatment PolicyCHHS Medication Handling PolicyProceduresCHHS Healthcare Associated Infections Clinical ProcedureCHHS Patient Identification and Procedure Matching PolicyCHHS Admission to Discharge ProcedureCHHS Medication ManagementLegislationHealth Records (Privacy and Access) Act 1997Human Rights Act 2004? Work Health and Safety Act 2011Back to Table of ContentsReferencesTrenkwalder, C., Chaudhuri, K. R., Ruiz, P. J. G., LeWitt, P., Katzenschlager, R., Sixel-Doring, F., Henriksen, T., Sesar, A., Poewe, W., Baker, M., Ceballos-Baumann, A., Deuschl, G., Drapier, S., Ebersbach, G., Evans, A., Fernandez, H., Isaacson, S., van Laar, T., Lees, A., Lewis, S., Castrillo, J. C. M., Martinez-Martin, P., Odin, P., O'Sullivan, J., Tagaris, G., Wenzel, K., Expert Consensus Grp Use, Apomorphi; Expert consensus group report on the use of apomorphine in the treatment of parkinson's disease - clinical practice recommendations, Parkinsonism Relat. Disord. 2015 Sep; 21:1023-1030Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, Castro García A, Alonso Frech F, Alvarez López M, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord 2008;23:1130-6.Back to Table of ContentsDefinition of Terms Dyskinesia – unnatural involuntary random movement‘ON’ – patient reports ‘normal’ or optimal movement ability‘OFF’ – patient displays bradykinesia/rigidity/tremorBradykinesia – slow or absent movementsTremor – rhythmic involuntary movement at rest or with actionRigidity – the feeling resistance when moving the patients relaxed limb. The patient will report feeling ‘stiff’Levodopa Induced Dyskinesia – dyskinesia induced as a result of levodopa treatmentBack to Table of ContentsSearch Terms Parkinson’s, Apomorphine, Challenge, Initiation, Crono Pump, InfusionBack to Table of ContentsAttachments Attachment 1 – Tomlinson Levodopa Conversion TableAttachment 2 – Patient selection guidelines for commencement of Apomorphine therapyAttachment 3 – Joint Position Statement on Apomorphine HydrochlorideDisclaimer: This document has been developed by ACT Health, Canberra Hospital and Health Services specifically for its own use. Use of this document and any reliance on the information contained therein by any third party is at his or her own risk and Health Directorate assumes no responsibility whatsoever.Policy Team ONLY to complete the following:Date AmendedSection AmendedDivisional ApprovalFinal Approval 24/01/2018Complete ReviewKellie Noffke, A/g DON MedicineCHHS Policy CommitteeThis document supersedes the following: Document NumberDocument NameCHHS13/268Apomorphine Initiation of in Patients with Parkinson’s diseaseAttachment 1 – Tomlinson Levodopa Conversion TableTomlinson et al. (2010). Systematic review of levodopa dose equivalency reporting in Parkinson's disease.Attachment 2 – Patient Selection Guidelines for Commencement of Apomorphine TherapyApomorphine is a viable therapy for patients who experience fluctuating motor symptom control using oral dopaminergic therapy. Candidates must be Levodopa responsive to be considered for Apomorphine therapy. A post Apomorphine percentage response improvement of at least 30% must be achieved during the Apomorphine challenge to proceed with treatment. With physician discretion and patient discussion 25% may be considered acceptable; determined on case to case basis.Candidates must be able to, or have a full-time carer able to, administer the injections/change pump cartridge. Patient symptoms/indicationsApomorphine Intermittent Subcutaneous Injection (Pen)Apomorphine Continuous Subcutaneous Infusion (Pump)Predictable or unpredictable ‘OFF’ periods Impairment of oral levodopa absorption (i.e. gastroparesis)To treat delayed ‘ON’ Consider other options firstEarly morning akinesia/dystoniaConsider other options firstDyskinesia’s limit further oral therapy optimisationComplex PD dosing regime and/or poor adherence to therapyxIntermittent injections required too oftenN/AContraindications:Known hypersensitivity or allergy to Apomorphine, morphine, or other sodium metabisulphites (sulphur)Known neuropsychiatric condition, or hallucinations with other Dopamine agonistsDiagnosed dementiaSevere dyskinesia’s during ‘ON’ periods (dopaminergic therapy should be optimised) Poor renal/liver functionUnstable cardiovascular diseaseCerebrovascular diseaseRespiratory depression or CNS depression.Attachment 3 – Joint Position Statement on Apomorphine Hydrochloride ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- office based opioid treatment obot policy and procedure
- apomorphine treatment guidelines for initiation
- lippincott williams wilkins
- american association of neuroscience nurses
- policy and procedures university of florida
- summary of treatment of parkinsons disease
- donor network of az pediatric organ donor management
- psychopharmacolgy
- nmem coi instructions to field reviewers
Related searches
- stemi treatment guidelines 2018
- chf treatment guidelines 2019
- hypertension treatment guidelines 2019 pdf
- treatment guidelines for cough
- cdc influenza treatment guidelines 2019
- conjunctivitis treatment guidelines 2019
- wcb medical treatment guidelines reference
- nys medical treatment guidelines 2018
- cad treatment guidelines aha
- hypertension treatment guidelines 2019
- osteopenia treatment guidelines 2019 pdf
- stemi treatment guidelines aha